Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab

 
• By Joseph Haas
SC2001_M-A_730858819_1200.jpg
Lilly makes a big M&A deal around the JPM meeting for a second straight year

More from Deals

More from Business